Rx Numbers for Gralise were flat but didn't warrant this kind of selloff. Perhaps an institution sold a chunk and leaned on the stock quickly. Roth Capital needs to update their reports to put Serada risk out of their equation. They give it zero value, but still give it an imputed FDA risk (even though funding has been discontinued).
I've researched this company, and I truly believe investors are confused. DEPO has no debt and a relatively good cash position. Granted, that while the new product pipeline is not stellar, the future for this organization appears to be fairly good with a current value of about $9 per share. Again, I believe investors are confused and perhaps the messaging has been poor or unclear from the organization itself.